Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032158 · ClinicalTrials.gov registry record · Phase 3
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT04032158 is a Phase 3 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 3 participants.
The verdict
NCT04032158, a Phase 3 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
Interventions
- DRUG Avonex®
- DRUG Evobrutinib
- DRUG Avonex® matched Placebo
- DRUG Evobrutinib matched Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032158
The ClinicalTrials.gov registry entry for NCT04032158 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Avonex® is the first listed.
NCT04032158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032158 about?
NCT04032158 is a clinical study titled "Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)". The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
What is the current status of trial NCT04032158?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2019-08-26. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT04032158?
The interventions under investigation include: Avonex® (DRUG), Evobrutinib (DRUG), Avonex® matched Placebo (DRUG), Evobrutinib matched Placebo (DRUG).
Who is sponsoring clinical trial NCT04032158?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.